Davern Capital Partners, LP
13F Reported Value
ⓘ$586.5M
Holdings
15
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Davern Capital Partners, LP disclosed 15 positions worth $586.5M in its Form 13F-HR for Q2 2026, led by $BNTX (BioNTech SE) at 12.0% of the equity portfolio, followed by $ROIV and $RPRX. During the quarter the fund opened 3 new positions and exited 5 — including a new stake in $ALNY and a full exit from $PFE. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Davern Capital Partners, LP’s Form 13F-HR filing with the SEC under CIK 2003147.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$70.2M754,550 sh - —
Quality
$68.4M1,932,904 sh - —
Quality
$64.8M1,155,809 sh - 23.4
Quality
$63.3M798,709 sh - 39.4
Quality
$59.7M559,824 sh - 71.0
Quality
$57.8M92,640 sh - 47.8
Quality
$34.4M1,191,522 sh - 71.4
Quality
$34.0M113,085 sh - 53.5
Quality
$32.3M118,975 sh - —
Quality
$23.9M446,059 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 BioNTech SE$BNTX | — | $70.2M | 754,550 |
 Roivant Sciences Ltd.$ROIV | — | $68.4M | 1,932,904 |
 Royalty Pharma plc$RPRX | — | $64.8M | 1,155,809 |
 IONIS PHARMACEUTICALS INC$IONS | 23.4 | $63.3M | 798,709 |
 INSMED Inc$INSM | 39.4 | $59.7M | 559,824 |
 REGENERON PHARMACEUTICALS, INC.$REGN | 71.0 | $57.8M | 92,640 |
 Legend Biotech Corp$LEGN | 47.8 | $34.4M | 1,191,522 |
 ALNYLAM PHARMACEUTICALS, INC.$ALNY | 71.4 | $34.0M | 113,085 |
 Natera, Inc.$NTRA | 53.5 | $32.3M | 118,975 |
 Structure Therapeutics Inc.$GPCR | — | $23.9M | 446,059 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Davern Capital Partners, LP's 15 positions.
Showing top 10 of 15 holdings.
Sector Allocation
Healthcare
$586.5M
Full Holdings — Davern Capital Partners, LP (Q2 2026)
All 15 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $BNTX | BioNTech SE | $70.2M | 12.0% | +147% | — |
| 2 | $ROIV | Roivant Sciences Ltd. | $68.4M | 11.7% | +121% | — |
| 3 | $RPRX | Royalty Pharma plc | $64.8M | 11.1% | +122% | — |
| 4 | $IONS | IONIS PHARMACEUTICALS INC | $63.3M | 10.8% | +106% | 23.4 |
| 5 | $INSM | INSMED Inc | $59.7M | 10.2% | +207% | 39.4 |
| 6 | $REGN | REGENERON PHARMACEUTICALS, INC. | $57.8M | 9.8% | +107% | 71 |
| 7 | $LEGN | Legend Biotech Corp | $34.4M | 5.9% | -9% | 47.8 |
| 8 | $ALNY | ALNYLAM PHARMACEUTICALS, INC. | $34.0M | 5.8% | NEW | 71.4 |
| 9 | $NTRA | Natera, Inc. | $32.3M | 5.5% | -17% | 53.5 |
| 10 | $GPCR | Structure Therapeutics Inc. | $23.9M | 4.1% | +253% | — |
| 11 |  $MLYS | Mineralys Therapeutics, Inc. | $23.2M | 4.0% | +92% | — |
| 12 |  $VERA | Vera Therapeutics, Inc. | $21.4M | 3.6% | NEW | — |
| 13 |  $GENB | Generate Biomedicines, Inc. | $13.9M | 2.4% | +39% | — |
| 14 |  $PRCT | PROCEPT BioRobotics Corp | $10.5M | 1.8% | +78% | 33.3 |
| 15 |  $AVTX | Avalo Therapeutics, Inc. | $8.7M | 1.5% | NEW | 11.7 |
New Positions (3)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Davern Capital Partners, LP including:
Track Davern Capital Partners, LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Davern Capital Partners, LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Davern Capital Partners, LP
13F Pro is an AI hedge fund tracker and stock research platform. For Davern Capital Partners, LP (SEC CIK: 2003147), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Davern Capital Partners, LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.